Linda Aoues

Launched in October 2020, SAI is a Micro-VC founded by 60 like-minded investors. We search for entrepreneurs that have taken their ideas from proof of concept to customer traction to scale with drive, energy, determination and ambition. We invest in the Seed and Series A rounds of early-stage technology companies with high growth potential. We are a fully-capitalized investment company and our angels range from seasoned investors, tech entrepreneurs, venture fund partners, senior executives. We utilize our collective experience with our extensive network of contacts to add value to our investees through our ability to open doors and to mentor them. We aim to invest between $50,000 to $150,000 in each of the companies we select, and our founders will be looking to co-invest in exceptional deals. We aim to keep a reserve to deploy additional capital to support the growth of our portfolio companies that shows great potential.

Allergan is now part of AbbVie. AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on LinkedIn for future updates.

Launched in October 2020, SAI is a Micro-VC founded by 60 like-minded investors. We search for entrepreneurs that have taken their ideas from proof of concept to customer traction to scale with drive, energy, determination and ambition. We invest in the Seed and Series A rounds of early-stage technology companies with high growth potential. We are a fully-capitalized investment company and our angels range from seasoned investors, tech entrepreneurs, venture fund partners, senior executives. We utilize our collective experience with our extensive network of contacts to add value to our investees through our ability to open doors and to mentor them. We aim to invest between $50,000 to $150,000 in each of the companies we select, and our founders will be looking to co-invest in exceptional deals. We aim to keep a reserve to deploy additional capital to support the growth of our portfolio companies that shows great potential.

Allergan is now part of AbbVie. AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on LinkedIn for future updates.